Abstract |
Several formulations and concentrations of topical fluorouracil have received US Food and Drug Administration (FDA) approval for the treatment of actinic keratosis (AK). The most commonly used are the fluorouracil 5% and 0.5% creams. In clinical trials, these formulations have demonstrated a marked ability to partially and completely eradicate AK lesions. Application site irritation, erythema, and burning are common side effects of both formulations, but comparative data suggest that the fluorouracil 0.5% cream is more cost-effective and may be safer, more tolerable, and as efficacious as fluorouracil 5% cream.
|
Authors | Joseph L Jorizzo, Patrick S Carney, William T Ko, Perry Robins, Susan H Weinkle, Wm Philip Werschler |
Journal | Cutis
(Cutis)
Vol. 74
Issue 6 Suppl
Pg. 18-23
(Dec 2004)
ISSN: 0011-4162 [Print] United States |
PMID | 15666898
(Publication Type: Comparative Study, Journal Article, Review)
|
Chemical References |
- Antimetabolites, Antineoplastic
- Emulsions
- Fluorouracil
|
Topics |
- Administration, Cutaneous
- Antimetabolites, Antineoplastic
(administration & dosage, economics, pharmacokinetics)
- Drug Administration Schedule
- Emulsions
- Fluorouracil
(administration & dosage, economics, pharmacokinetics)
- Humans
- Keratosis
(drug therapy)
- Photosensitivity Disorders
(drug therapy)
- Therapeutic Equivalency
|